ArticleEuropean journal of nuclear medicine and molecular imaging2024
SSTR antagonist [
Weizhi Xu, Jiayu Cai, Tinghua Meng, YiZhen Pang, Haojun Chen
Abstract readCase Reports
In one paragraphArticle in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
5 authors at 1 institution in 1 country.
Weizhi Xu *Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Jiayu Cai *Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Tinghua MengDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
YiZhen PangDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Haojun ChenDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. leochen0821@foxmail.com.ORCID 0000-0002-9101-8884 First Affiliated Hospital of Xiamen University · CN
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Neuroendocrine TumorsOrganometallic CompoundsGallium RadioisotopesHeterocyclic Compounds, 1-RingHumansMagnetic Resonance ImagingPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadionuclide ImagingReceptors, SomatostatinSpleen1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidcopper dotatate CU-64Gallium RadioisotopesHeterocyclic Compounds, 1-RingOrganometallic CompoundsReceptors, Somatostatin
Identifiers
PMID37715815
OpenAlexW4386803464
What OpenQuestion holds
Textmetadata
Read underepoch 390